These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24753160)

  • 21. Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.
    Wassmer G
    J Biopharm Stat; 2003 Nov; 13(4):585-603. PubMed ID: 14584710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Internal pilots for observational studies.
    Gurka MJ; Coffey CS; Gurka KK
    Biom J; 2010 Oct; 52(5):590-603. PubMed ID: 20857422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
    Dunnigan K; King DW
    Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials.
    Wang SJ; James Hung HM; O'Neill RT
    Biom J; 2010 Dec; 52(6):798-810. PubMed ID: 21154897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
    Ayanlowo AO; Redden DT
    Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
    Lin J; Bunn V
    Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modifying the design of ongoing trials without unblinding.
    Gould AL; Shih WJ
    Stat Med; 1998 Jan; 17(1):89-100. PubMed ID: 9463852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blinded sample size re-estimation in crossover bioequivalence trials.
    Golkowski D; Friede T; Kieser M
    Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive graph-based multiple testing procedures.
    Klinglmueller F; Posch M; Koenig F
    Pharm Stat; 2014; 13(6):345-56. PubMed ID: 25319733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlling the family-wise error rate in multi-arm, multi-stage trials.
    Crouch LA; Dodd LE; Proschan MA
    Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches.
    Shih WJ; Li G; Wang Y
    Contemp Clin Trials; 2016 Mar; 47():40-8. PubMed ID: 26674739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.